Published in Thromb Haemost on January 25, 2012
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18
Double-hit B-cell lymphomas. Blood (2010) 3.19
High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation (2007) 2.07
High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost (2009) 1.64
Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr (2005) 1.59
The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica (2005) 1.58
Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol (2010) 1.54
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.42
Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol Dial Transplant (2010) 1.42
Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. Thromb Haemost (2014) 1.40
Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol (2004) 1.28
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood (2005) 1.28
Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica (2006) 1.15
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol (2008) 1.10
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol (2014) 1.10
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol (2013) 1.09
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood (2004) 1.08
Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene (2003) 1.08
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev (2007) 1.07
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2012) 1.07
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood (2010) 0.97
Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol (2011) 0.97
Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant (2005) 0.94
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood (2008) 0.92
Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol (2007) 0.90
HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation (2005) 0.90
In normal controls, both age and gender affect coagulability as measured by thrombelastography. Anesth Analg (2010) 0.90
Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol (2005) 0.85
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol (2014) 0.84
A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis. Haematologica (2013) 0.83
Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma (2005) 0.83
Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica (2009) 0.83
Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood (2008) 0.82
Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost (2011) 0.82
Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study. Thromb Res (2010) 0.81
The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med (2006) 0.81
An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom (2008) 0.81
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2011) 0.81
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol (2004) 0.81
Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. Thromb Haemost (2012) 0.81
The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr (2004) 0.81
Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia. Haematologica (2005) 0.80
Active cytomegalovirus infection in patients with acute venous thrombosis: a case-control study. Am J Hematol (2011) 0.80
Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study. Br J Haematol (2012) 0.80
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr (2012) 0.80
Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol (2012) 0.79
Management of mantle cell lymphoma in the elderly patient. Clin Interv Aging (2013) 0.79
Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography. Blood Coagul Fibrinolysis (2010) 0.79
Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. Haematologica (2009) 0.79
The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. Am J Obstet Gynecol (2013) 0.79
Characterisation of hairy cell leukaemia by tiling resolution array-based comparative genome hybridisation: a series of 13 cases and review of the literature. Eur J Haematol (2010) 0.79
Contribution of multiple thrombophilic and transient risk factors in the development of cerebral venous thrombosis. Thromb Res (2007) 0.78
Effects of red blood cells on hemostasis. Transfusion (2010) 0.78
The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. Thromb Res (2012) 0.78
Lenalidomide therapy in systemic mastocytosis. Leuk Res (2008) 0.78
Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol (2008) 0.76
Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2006) 0.76
Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol (2012) 0.76
Low cut-off values increase diagnostic performance of protein S assays. Thromb Haemost (2010) 0.75
Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. Haematologica (2008) 0.75
[Anaemia caused by a congenital haemoglobin defect can also occur in native Dutch patients]. Ned Tijdschr Geneeskd (2011) 0.75
Pain and anxiety during bone marrow biopsy. Pain Manag Nurs (2011) 0.75
[AL amyloidosis-associated factor X deficiency]. Ned Tijdschr Geneeskd (2014) 0.75
Decreased free protein S levels and venous thrombosis in the acute setting, a case-control study. Thromb Res (2011) 0.75
Routine evaluation and treatment of unexplained menorrhagia: do we consider haemostatic disorders? Eur J Obstet Gynecol Reprod Biol (2010) 0.75
Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. Clin Lymphoma Myeloma (2005) 0.75
Positive blood culture with Plasmodium falciparum: case report. Am J Trop Med Hyg (2007) 0.75
Identification of a novel factor XI gene mutational event in a Dutch Caucasian family with inherited factor XI deficiency. Thromb Haemost (2013) 0.75
Splenectomy and second malignancies in patients with Hodgkin lymphoma. Leuk Lymphoma (2014) 0.75
The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3. J Immunol (2004) 0.75
Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leuk Lymphoma (2011) 0.75
Identification of a novel PROS1 c.1113T-->GG frameshift mutation in a family with mixed type I/type III protein S deficiency. Haematologica (2006) 0.75
Sinusoidal endothelial cells are damaged and display enhanced autophagy in myelodysplastic syndromes. Br J Haematol (2013) 0.75
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica (2005) 0.75
A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. Br J Haematol (2007) 0.75